Lung cancer biomarkers in exhaled breath

Expert Review of Molecular Diagnostics

Volumn 11, Issue 2, 2011, Pages 207-217

  Amann, Anton ^a,b   Corradi, Massimo ^c   Mazzone, Peter ^d   Mutti, Antonio ^c  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF PARMA   (Italy)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

exhaled breath; exhaled breath condensate; exhaled nonvolatile biomarkers; gas chromatography; lung cancer; screening; sensors; smoking; volatile organic compounds

Indexed keywords

ACETONITRILE; ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BENZENE; BIOLOGICAL MARKER; CYTOCHROME P450; DECANE; ENDOTHELIN 1; EOTAXIN; ETHYLBENZENE; FIBROBLAST GROWTH FACTOR; HEPTANE; INTERLEUKIN 10; INTERLEUKIN 6; ISOPRENE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; METHYL PENTANE; OCTANE; PENTAMETHYLHEPTANE; PENTANE; PROTEIN P53; STYRENE; TOLUENE; UNCLASSIFIED DRUG; VOLATILE ORGANIC COMPOUND; XYLENE;

BREATH ANALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORIMETRY; DNA METHYLATION; EXHALATION; EXPIRED AIR; FIBROSING ALVEOLITIS; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SARCOIDOSIS; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METHYLATION; PROTON TRANSFER REACTION MASS SPECTROMETRY; PROTON TRANSPORT; PULMONARY HYPERTENSION; REVIEW; SENSOR; SOLID PHASE MICROEXTRACTION;

BREATH TESTS; EXHALATION; HUMANS; LUNG NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VOLATILE ORGANIC COMPOUNDS;

EID: 79952925062     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.112     Document Type: Review

References (97)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 2009. 59(4), 225-249 (2009).
2. Damber LA, Larsson LG. Smoking and lung cancer with special regard to type of smoking and type of cancer. A case-control study in north Sweden. Br. J. Cancer 53(5), 673-681 (1986). (Pubitemid 16114628)
3. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 136(1), 260-271 (2009).
4. Damhuis RA, Schutte PR. Resection rates and postoperative mortality in 7899 patients with lung cancer. Eur. Respir. J. 9(1), 7-10 (1996). (Pubitemid 26037523)
5. Little AG, Rusch VW, Bonner JA et al. Patterns of surgical care of lung cancer patients. Ann. Thorac. Surg. 80(6), 2051-2056 (2005). (Pubitemid 41718027)
6. Mazzone PJ, Mekhail T. Lung cancer screening. Curr. Oncol. Rep. 9(4), 265-274 (2007). (Pubitemid 47045161)
7. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: The Lung Screening Study of the National Cancer Institute. Chest 126(1), 114-121 (2004). (Pubitemid 38943126)
8. Infante M, Cavuto S, Lutman FR et al. A randomized study of lung cancer screening with spiral computed tomography: Three-year results from the DANTE trial. Am. J. Respir. Crit. Care Med. 180(5), 445-453 (2009).
9. Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 355(17), 1763-1771 (2006). (Pubitemid 44631359)
10. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 297(9), 953-961 (2007).Screening for lung cancer with low-dose computed tomography may increase the rate of lung cancer diagnosis and treatment, but may not necessarily reduce the risk of advanced lung cancer or death from lung cancer. (Pubitemid 46376749)
11. Gierada DS, Pilgram TK, Ford M et al. Lung cancer: Interobserver agreement on interpretation of pulmonary findings at low-dose CT screening. Radiology 246(1), 265-272 (2008). (Pubitemid 350305052)
12. Altman DG. Practical Statistics for Medical Research (1st Edition). Chapman and Hall, London, UK (1991).
13. Roberts HC, Patsios D, Paul NS et al. Lung cancer screening with low-dose computed tomography: Canadian experience. Can. Assoc. Radiol. J. 58(4), 225-235 (2007). (Pubitemid 350021946)
14. Swensen SJ, Jett JR, Hartman TE et al. CT screening for lung cancer: Five-year prospective experience. Radiology 235(1), 259-265 (2005). (Pubitemid 40432263)
15. Flake GP, Rivera MP, Funkhouser WK et al. Detection of pre-invasive lung cancer: Technical aspects of the LIFE project. Toxicol. Pathol. 35(1), 65-74 (2007). (Pubitemid 46328408)
16. Amann A, Poupart G, Telser S, Ledochowski M, Schmid A, Mechtcheriakov S. Applications of breath gas analysis in medicine. Int. J. Mass Spect. 239, 227-233 (2004).
17. Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore (2005).
18. Amann A, Spanel P, Smith D. Breath analysis: The approach towards clinical applications. Mini Rev. Med. Chem. 7(2), 115-129 (2007). (Pubitemid 46592175)
19. Amann A, Telser S, Hofer L, Schmid A, Hinterhuber H. Exhaled breath as a biochemical probe during sleep. In:Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore, 305-316 (2005).
20. Bajtarevic A, Ager C, Pienz M et al. Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 9(1), 348 (2009).In this article, approximately 100 compounds contained in the exhaled breath of lung cancer patients are not only identified by spectral library identification, but also by retention time comparison with native standards.
21. Eisenmann A, Amann A, Buchberger W, Said M, Datta B, Ledochowski M. Execution and interpretation of hydrogen breath tests. J. Breath Res. 2, 046002 (9pp) (2008).
22. Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. 13C-5-FU breath test current status and future directions: A comprehensive review. J. Breath Res. 3(4), 047002 (2009).The 13C-uracil breath test for dihydropyrimidine dehydrogenase deficiency is a very elegant breath test based on an isotopically labeled precursor. Such breath tests will play a very important role in the future.
23. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101(1), 113-121 (2007).The dextromethorphan breath test is a paradigmatic example for determination of CYP450-activity. The results are immediately applicable to stratification of breast cancer patients undergoing tamoxifen therapy. (Pubitemid 47555336)
24. King J, Kupferthaler A, Unterkofler K et al. Isoprene and acetone concentration profiles during exercise at an ergometer. J. Breath Res. 3, 027006 (16pp) (2009).Demonstrates that the isoprene concentration in exhaled breath can change by a factor of approximately five during exercise. Hence, lower isoprene concentrations in exhaled breath of lung cancer patients compared with healthy controls should be treated with great care.
25. Kushch I, Arendacka B, Stolc S et al. Breath isoprene-aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin. Chem. Lab. Med. 46, 1011-1018 (2008). (Pubitemid 352000486)
26. Corradi M, Rubinstein I, Andreoli R et al. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 167(10), 1380-1386 (2003). (Pubitemid 36609723)
27. Mattison L, Johnson M, Saif W et al. Validation of a novel [2-13C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-13C]-uracil (URA) and [2-13C]-dihydrouracil (DHU) plasma levels. J. Clin. Oncol. 22(14S), 2130 (2004).
28. Modak A. 13C breath tests: Transition from research to clinical practice. In:Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore, 457-478 (2005).
29. Phillips M, Gleeson K, Hughes JM et al. Volatile organic compounds in breath as markers of lung cancer: A cross-sectional study. Lancet 353(9168), 1930-1933 (1999).For the first time in medicine, the term 'breathalyzer' is used for lung cancer. In patients with an abnormal chest radiograph, a combination of 22 volatile organic compounds in breath samples distinguished between patients with and without lung cancer. (Pubitemid 29255706)
30. Poli D, Carbognani P, Corradi M et al. Exhaled volatile organic compounds in patients with non-small cell lung cancer: Cross sectional and nested short-term follow-up study. Respir. Res. 6(1), 71 (2005).
31. Wehinger A, Schmid A, Mechtcheriakov S et al. Lung cancer detection by proton transfer reaction mass spectrometric analysis of human breath gas. Int. J. Mass Spec. 265, 49-59 (2007).
32. Manolis A. The diagnostic potential of breath analysis. Clin. Chem. 29(1), 5-15 (1983). (Pubitemid 13167610)
33. Bloor R, Wang T, Spanel P, Smith D. Applications of selected ion flow tube mass spectrometry, SIFT-MS, in addiction research. In:Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore, 409-427 (2005).
34. Davies S, Spanel P, Smith D. Quantitative analysis of ammonia on the breath of patients in end-stage renal failure. Kidney Int. 52(1), 223-228 (1997).Pioneering article on exhaled-breath analysis of patients suffering from renal disease. (Pubitemid 27321835)
35. Davies S, Spanel P, Smith D. A new 'online' method to measure increased exhaled isoprene in end-stage renal failure. Nephrol. Dial. Transplant. 16(4), 836-839 (2001). (Pubitemid 32257985)
36. Davies S, Spanel P, Smith D. Rapid measurement of deuterium content of breath following oral ingestion to determine body water. Physiol. Meas. 22(4), 651-659 (2001).Pioneering article on determination of total body water by exhaled-breath analysis. (Pubitemid 33104652)
37. Schubert J, Miekisch W, Nöldge- Schomburg G. VOC breath markers in critically ill patients: Potentials and limitations. In:Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore, 267-292 (2005).
38. Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. Volatile biomarkers in the breath of women with breast cancer. J. Breath Res. 4(2), 026003 (2010).
39. Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ. Volatile organic compounds in exhaled air from patients with lung cancer. Clin. Chem. 31(8), 1278-1282 (1985).First report where exhaled volatile organic compounds were collected using a specially developed breath-collection technique and analyzed by computerassisted gas chromatography/ mass spectrometry. (Pubitemid 16041914)
40. Kischkel S, Miekisch W, Sawacki A et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects-confounding variables, influence of normalization and statistical algorithms. Clin. Chim. Acta 411(21-22), 1637-1644 (2010).
41. Cope KA, Watson MT, Foster WM, Sehnert SS, Risby TH. Effects of ventilation on the collection of exhaled breath in humans. J. Appl. Physiol. 96(4), 1371-1379 (2004). (Pubitemid 38392673)
42. King J, Mochalski P, Kupferthaler A et al. Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. Physiol. Meas. 31(9), 1169-84 (2010).
43. King J, Koc H, Unterkofler K et al. Physiological modeling of isoprene dynamics in exhaled breath. J. Theor. Biol. 267, 626-637 (2010).Pioneering article on the modeling of isoprene in the human body using real-time analysis of exhaled breath.
44. Ligor M, Ligor T, Bajtarevic A et al. Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin. Chem. Lab. Med. 47(5), 550-560 (2009).
45. Tu RH, Mitchell CS, Kay GG. Human exposure to the jet fuel, JP-8. Aviat. Space Environ. Med. 75(1), 49-59 (2004).Exogenous compounds, such as those from jet fuel or gasoline, may accumulate in the body and subsequently be exhaled. These are confounding factors that should be taken into account. (Pubitemid 38040664)
46. Krkosova Z, Kubinec R, Sojak L, Amann A. Temperature-programmed gas chromatography linear retention indices of all C4-C30 monomethylalkanes on methylsilicone OV-1 stationary phase. Contribution towards a better understanding of volatile organic compounds in exhaled breath. J. Chromatogr. A. 1179(1), 59-68 (2008).Monomethylated alkanes have been pioneered by Michael Phillips. In this article, retention times of monomethylated alkanes are determined for all C4-C30 monomethylated alkanes. This allows for validated identification of the methylation position in hydrocarbons. (Pubitemid 350309605)
47. Sponring A, Filipiak W, Mikoviny T et al. Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 29(1), 419-426 (2009).
48. Filipiak W, Sponring A, Filipiak A et al. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol. Biomarkers Prev. 19(1), 182-195 (2010).In this article, headspace of lung cancer cell lines are investigated and compared with respective noncancerous cell lines. The compounds observed are not only identified by spectral library identification, but also by retention time comparison with native standards.
49. Filipiak W, Sponring A, Mikoviny T et al. Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int. 8(1), 17 (2008).
50. Poli D, Goldoni M, Caglieri A et al. Breath analysis in non small cell lung cancer patients after surgical tumour resection. Acta Biomed. 79(Suppl. 1), 64-72 (2008).
51. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin. Cancer Res. 10(8), 2652-2658 (2004). (Pubitemid 38509138)
52. Modak A. Editorial: Breath tests with 13C substrates. J. Breath Res. 3(4), 040201 (2009).
53. Modak AS. Single time point diagnostic breath tests: A review. J. Breath Res. 4(1), 017002 (2010).
54. Erhart S, Amann A, Karall D et al. 3-heptanone as a potential new marker for valproic acid therapy. J. Breath Res. 3, 016004 (6 pp) (2009).New breath tests using isotopically labeled precursors could be based on 'target compounds' that do not normally appear in exhaled breath. An example would be 3-heptanone (described in this article), which is produced from its precursor valproic acid through carboxylation.
55. Leeder JS, Pearce RE, Gaedigk A, Modak A, Rosen DI. Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype. J. Clin. Pharmacol. 48(9), 1041-1051 (2008).The dextromethorphan breath test is a paradigmatic example for determination of cytochrome P450 activity. The results are immediately applicable to stratification of breast cancer patients undergoing tamoxifen therapy.
56. Chen X, Xu FJ, Wang Y et al. A study of the volatile organic compounds exhaled by lung cancer cells in vitro for breath diagnosis. Cancer 110(4), 835-844 (2007). (Pubitemid 47257662)
57. Ligor T, Ligor M, Amann A et al. The analysis of healthy volunteers' exhaled breath by the use of solid-phase microextraction and GC-MS. J. Breath Res. 2, 046006 (2008).
58. Buszewski B, Kesy M, Ligor T, Amann A. Human exhaled air analytics: Biomarkers of diseases. Biomed. Chromatogr. 21(6), 553-566 (2007). (Pubitemid 46937852)
59. Buszewski B, Ulanowska A, Ligor T, Denderz N, Amann A. Analysis of exhaled breath from smokers, passive smokers and non-smokers by solid-phase microextraction gas chromatography/mass spectrometry. Biomed. Chromatogr. 23(5), 551-556 (2009).
60. Miekisch W, Kischkel SAS, Liebau T, Mieth M, Schubert JK. Impact of sampling procedures on the results of breath analysis. J. Breath Res. 2, 026007 (2008).Conclusively describes how the sampling procedure is most critical for exhaled breath investigation.
61. Mochalski P, Wzorek B, Sliwka I, Amann A. Suitability of different polymer bags for storage of volatile sulphur compounds relevant to breath analysis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877(3), 189-196 (2009).
62. Wzorek B, Sliwka I, Mochalski P, Amann A. Application of GC-MS with a SPME and thermal desorption technique for determination of dimethylamine and trimethylamine in gaseous samples for medical diagnostic purposes. J. Breath Res. 4, 026002 (2010).
63. Halmer D, von Basum G, Hering P, Murtz M. Mid-infrared cavity leak-out spectroscopy for ultrasensitive detection of carbonyl sulfide. Opt. Lett. 30(17), 2314-2316 (2005). (Pubitemid 41345881)
64. Lee PS, Majkowski RF, Perry TA. Tunable diode laser spectroscopy for isotope analysis-detection of isotopic carbon monoxide in exhaled breath. IEEE Trans. Biomed. Eng. 38(10), 966-973 (1991).
65. Parameswaran KR, Rosen DI, Allen MG, Ganz AM, Risby TH. Off-axis integrated cavity output spectroscopy with a mid-infrared interband cascade laser for real-time breath ethane measurements. Appl. Opt. 48(4), B73-B79 (2009).Laser spectrometry has great potential for miniaturization. Adapted to particular compounds (e.g., ethane), it can measure with breath-to-breath resolution and down to parts-per-trillion concentration levels.
66. Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: Results of a pilot study. Thorax 64(9), 744-748 (2009).Ion mobility spectrometry is a technique with great potential for miniaturization in the near future. It is very sensitive and particularly suited to the detection of aldehydes and ketones.
67. Rudnicka J, Mochalski P, Agapiou A, Statheropoulos M, Amann A, Buszewski B. Application of ion mobility spectrometry for the detection of human urine. Anal. Bioanal. Chem. 398(5), 2031-2038 (2010).Ion mobility spectrometry is a technique with great potential for miniaturization in the near future. It is very sensitive and particularly suited to the detection of aldehydes and ketones.
68. Basanta M, Jarvis RM, Xu Y et al. Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst 135(2), 315-320 (2010).
69. Machado RF, Laskowski D, Deffenderfer O et al. Detection of lung cancer by sensor array analyses of exhaled breath. Am. J. Respir. Crit. Care Med. 171(11), 1286-1291 (2005).Sensors will provide a comparatively inexpensive way to analyze breath in the future and have great clinical potential. (Pubitemid 40740737)
70. Mazzone PJ, Hammel J, Dweik R et al. Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax 62(7), 565-568 (2007).The use of a colorimetric sensor array for analysis of exhaled breath was pioneered in this article. (Pubitemid 47056880)
71. Di Natale C, Macagnano A, Martinelli E et al. Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens. Bioelectron. 18(10), 1209-1218 (2003).Sensors will provide a comparatively inexpensive way to analyze breath in the future and have great clinical potential. (Pubitemid 36776581)
72. McCulloch M, Jezierski T, Broffman M, Hubbard A, Turner K, Janecki T. Diagnostic accuracy of canine scent detection in early- and late-stage lung and breast cancers. Integr. Cancer Ther. 5(1), 30-39 (2006).Investigates the possibility of using the excellent canine olfactory sense to detect individuals with cancer. (Pubitemid 43260792)
73. Lim SH, Feng L, Kemling JW, Musto CJ, Suslick KS. An optoelectronic nose for detection of toxic gases. Nat. Chem. 1, 562-567 (2009).
74. Peng G, Tisch U, Adams O et al. Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat. Nanotechnol. 4(10), 669-673 (2009).Describes the use of chemically modified gold nanoparticles, which is a very promising technique for development of sensors and sensor arrays for use in medical diagnostics.
75. Barash O, Peled N, Hirsch FR, Haick H. Sniffing the unique 'odor print' of non-smallcell lung cancer with gold nanoparticles. Small 5(22), 2618-2624 (2009).
76. Hunt J. Exhaled breath condensate: An evolving tool for noninvasive evaluation of lung disease. J. Allergy Clin. Immunol. 110(1), 28-34 (2002). (Pubitemid 36132721)
77. Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int. J. Biol. Markers 17(2), 141-145 (2002). (Pubitemid 34873801)
78. Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E, Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology 66(3), 180-184 (2004). (Pubitemid 38813043)
79. Gessner C, Rechner B, Hammerschmidt S et al. Angiogenic markers in breath condensate identify non-small cell lung cancer. Lung Cancer 68(2), 177-184 (2010).
80. Gessner C, Kuhn H, Toepfer K, Hammerschmidt S, Schauer J, Wirtz H. Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients. Lung Cancer 43(2), 215-222 (2004). (Pubitemid 38114751)
81. Carpagnano GE, Foschino-Barbaro MP, Mule G et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am. J. Respir. Crit. Care Med. 172(6), 738-744 (2005). (Pubitemid 41324229)
82. Han W, Wang T, Reilly AA, Keller SM, Spivack SD. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir. Res. 10, 86 (2009).
83. Kullmann T, Barta I, Csiszer E, Antus B, Horvath I. Differential cytokine pattern in the exhaled breath of patients with lung cancer. Pathol. Oncol. Res. 14(4), 481-483 (2008).
84. Herbig J, Müller M, Schallhart S, Titzmann T, Graus M, Hansel A. On-line breath analysis with PTR-TOF. J. Breath Res. 3, 027004 (10pp) (2009).In this article, proton transfer reaction- TOF technology is used for the analysis of exhaled breath. Proton transfer reaction- TOF provides fast measurement of breath samples with a high mass resolution of approximately 1/5000.
85. Smith D. Spanel P. Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis. Mass Spectrom. Rev. 24(5), 661-700 (2005). (Pubitemid 41615714)
86. Risby T. Current status of clinical breath analysis. In:Breath Analysis for Clinical Diagnosis and Therapeutic Monitoring. Amann A, Smith D (Eds). World Scientific, Singapore, 251-265 (2005).
87. Risby TH. Critical issues for breath analysis. J. Breath Res. 2(3), 030302 (3pp) (2008).
88. Risby TH, Solga SF. Current status of clinical breath analysis. Appl. Phys. B 85(2-3), 421-426 (2006). (Pubitemid 44451363)
89. Amann A, Miekisch W, Pleil J, Risby T, Schubert W. Methodological issues of sample collection and analysis of exhaled breath. In: European Respiratory Society Monograph 49. Horvath I, de Jongste JC (Eds). European Respiratory Society, Lausanne, Switzerland, 96-114 (2010).
90. Risch A, Plass C. Lung cancer epigenetics and genetics. Int. J. Cancer 123(1), 1-7 (2008). (Pubitemid 351705185)
91. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol. 2(4), 327-343 (2007). (Pubitemid 47181718)
92. Wistuba II, Gazdar AF, Minna JD, Molecular genetics of small cell lung carcinoma. Semin. Oncol. 28(2 Suppl. 4), 3-13 (2001). (Pubitemid 32730372)
93. Castell JV, Donato MT, Gomez-Lechon MJ. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach. Exp. Toxicol. Pathol. 57(Suppl. 1), 189-204 (2005). (Pubitemid 40884492)
94. Chen TS, Chang FY, Chen PC et al. Simplified 13C-urea breath test with a new infrared spectrometer for diagnosis of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 18(11), 1237-1243 (2003).
95. Chen X, Cao MF, Li Y et al. A study of an electronic nose for detection of lung cancer based on a virtual SAW gas sensors array and imaging recognition method. Meas. Sci. Technol. 16(8), 1535-1546 (2005). (Pubitemid 41053390)
96. Peng G, Trock E, Haick H. Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials. Nano. Lett. 8(11), 3631-3635 (2008).
97. Dragonieri S, Annema JT, Schot R et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 64(2), 166-170 (2009).